NASDAQ:TRVN

Trevena Stock Forecast, Price & News

$1.91

+0.01 (+0.53 %)

(As of 06/18/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.90

▼

$2.00

50-Day Range

$1.46

▼

$2.25

52-Week Range

$1.34

▼

$3.68

Volume2.05 million shs

Average Volume3.35 million shs

Market Capitalization$312.46 million

P/E RatioN/A

Dividend YieldN/A

Beta2.46

30 days | 90 days | 365 days | Advanced Chart

Receive TRVN News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

About Trevena

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid - GlobeNewswire
June 16, 2021 | globenewswire.com

Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder
June 16, 2021 | finance.yahoo.com

Trevena to Present at the JMP Securities Life Sciences Conference - GlobeNewswire
June 9, 2021 | globenewswire.com

Trevena to Present at the JMP Securities Life Sciences Conference
June 9, 2021 | finance.yahoo.com

Analysts Anticipate Trevena, Inc. (NASDAQ:TRVN) Will Announce Quarterly Sales of $1.26 Million
June 6, 2021 | americanbankingnews.com

Analysts Expect Trevena, Inc. (NASDAQ:TRVN) to Announce -$0.08 Earnings Per Share
June 4, 2021 | americanbankingnews.com

Trevena Announces Presentations of OLINVYK® Health Economic Models at ISPOR 2021 - Yahoo Finance
May 21, 2021 | finance.yahoo.com

Trevena Announces Presentations of OLINVYK® Health Economic - GlobeNewswire
May 19, 2021 | globenewswire.com

Trevena Announces Presentations of OLINVYK® Health Economic Models at ISPOR 2021
May 19, 2021 | finance.yahoo.com

Trevena reports Olinvyk respiratory data in OIRD patients - Seeking Alpha
May 13, 2021 | seekingalpha.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TRVN
Previous Symbol
CUSIPN/A
CIK1429560
Webwww.trevena.com
Phone610-354-8840
Employees25
Year FoundedN/A

Sales & Book Value

Annual Sales$3.07 million
Price / Sales101.78
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.66 per share
Price / Book2.89

Profitability

EPS (Most Recent Fiscal Year)($0.23)
Net Income$-29,370,000.00
Net MarginsN/A
Return on Equity-36.33%
Return on Assets-30.78%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares163,593,000
Market Cap$312.46 million
Next Earnings Date8/9/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.46 out of 5 stars

Medical Sector

647th out of 2,100 stocks

Pharmaceutical Preparations Industry

316th out of 830 stocks

3.4 Analyst's Opinion

Consensus Rating
Trevena has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Trevena has a forecasted upside of 161.8% from its current price of $1.91.
Amount of Analyst Coverage
Trevena has received no research coverage in the past 90 days.

3.3 Community Rank

Outperform Votes
Trevena has received 611 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Trevena has received 315 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Trevena has received 65.98% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote “Outperform” if you believe TRVN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TRVN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Trevena does not currently pay a dividend.
Dividend Growth
Trevena does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Trevena insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.50% of the stock of Trevena is held by insiders.
Percentage Held by Institutions
Only 16.88% of the stock of Trevena is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Trevena are expected to grow in the coming year, from ($0.29) to ($0.26) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Trevena is -7.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Trevena is -7.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Trevena has a P/B Ratio of 2.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Trevena (NASDAQ:TRVN) Frequently Asked Questions

Is Trevena a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Trevena stock.
View analyst ratings for Trevena or view top-rated stocks.

What stocks does MarketBeat like better than Trevena?

Wall Street analysts have given Trevena a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Trevena wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Trevena's next earnings date?

Trevena is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Trevena.

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) announced its quarterly earnings data on Thursday, May, 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The biopharmaceutical company earned $0.21 million during the quarter, compared to analyst estimates of $0.55 million.
View Trevena's earnings history.

How has Trevena's stock been impacted by Coronavirus (COVID-19)?

Trevena's stock was trading at $0.6984 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TRVN shares have increased by 173.5% and is now trading at $1.91.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for TRVN?

4 Wall Street analysts have issued 1 year price objectives for Trevena's shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Trevena's share price to reach $5.00 in the next year. This suggests a possible upside of 161.8% from the stock's current price.
View analysts' price targets for Trevena or view top-rated stocks among Wall Street analysts.

Who are Trevena's key executives?

Trevena's management team includes the following people:

Ms. Carrie L. Bourdow, Pres, CEO & Director (Age 58, Pay $1.14M)
Mr. Scott Applebaum, Chief Legal & Compliance Officer, Sr. VP of Regulatory Affairs & Corp. Sec. (Age 54, Pay $605.31k)
Dr. Mark A. Demitrack, Sr. VP & Chief Medical Officer (Age 63, Pay $725.67k)
Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory Board
Mr. Barry Shin, Sr. VP & CFO (Age 49)
Mr. Michael Catalano, VP of Marketing
Mr. Robert T. Yoder, Sr. VP & Chief Commercial Officer (Age 55)

Who are some of Trevena's key competitors?

Some companies that are related to Trevena include Shattuck Labs (STTK), Endo International (ENDP), Phibro Animal Health (PAHC), CytoDyn (CYDY), Antibe Therapeutics (ATBPD), Theravance Biopharma (TBPH), Dyne Therapeutics (DYN), Phathom Pharmaceuticals (PHAT), Humanigen (HGEN), Vanda Pharmaceuticals (VNDA), MannKind (MNKD), PyroGenesis Canada (PYR), Akero Therapeutics (AKRO), Pliant Therapeutics (PLRX) and Kinnate Biopharma (KNTE).
View all of TRVN's competitors.

What other stocks do shareholders of Trevena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX).

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Who are Trevena's major shareholders?

Trevena's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.15%), Millennium Management LLC (1.28%), Geode Capital Management LLC (0.86%), HRT Financial LP (0.46%), Morgan Stanley (0.23%) and Renaissance Technologies LLC (0.18%).
View institutional ownership trends for Trevena.

Which institutional investors are selling Trevena stock?

TRVN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Squarepoint Ops LLC, Citigroup Inc., Royal Bank of Canada, and Bank of New York Mellon Corp.
View insider buying and selling activity for Trevena or view top insider-selling stocks.

Which institutional investors are buying Trevena stock?

TRVN stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., HRT Financial LP, Geode Capital Management LLC, Morgan Stanley, Polar Capital Holdings Plc, Goldman Sachs Group Inc., and Diametric Capital LP.
View insider buying and selling activity for Trevena or or view top insider-buying stocks.

How do I buy shares of Trevena?

Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $1.91.

How much money does Trevena make?

Trevena has a market capitalization of $312.46 million and generates $3.07 million in revenue each year. The biopharmaceutical company earns $-29,370,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis.

How many employees does Trevena have?

Trevena employs 25 workers across the globe.

What is Trevena's official website?

The official website for Trevena is www.trevena.com.

Where are Trevena's headquarters?

Trevena is headquartered at 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087.

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected]

This page was last updated on 6/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here